Expanding access to quality eye screening

Verily Retinal Service aims to reduce preventable blindness by empowering providers with technology that enables the detection of diabetic retinopathy (DR) by clinicians.

Building tools that bring the promise of precision health to everyone, every day.

Ninety percent of severe vision loss caused by diabetes is preventable with early detection and treatment strategies.1 Our holistic offering is primed to drive meaningful change for people with diabetes.

The Retinal Camera

Intuitive and easy to use

This lightweight and portable camera is built with advanced lighting and stabilization technology, making it easy for clinicians. It requires no dilation of the eye in most cases, making it easy for patients.2

Integrated Platform

Built for day-to-day workflow

Our software is built on a HIPAA secure cloud-based platform, which integrates seamlessly with EHRs and clinician workflows.

Addressing Gaps in Care

Bringing solutions where they're needed most

Born out of a real-world need and a long-standing collaboration between Google and Verily, Verily Retinal Service uniquely combines hardware, software and services, expanding access to quality eye screening.

Verily Retinal Services allows providers to integrate routine DR screening into existing workflows.

85% of people living with diabetes in the United States managed diabetes through primary care providers (PCPs).3

90% of severe vision loss caused by diabetes is preventable with early detection and treatment strategies.4

84% of patients would be comfortable getting screened by their PCP, however only 14% have been screened at their PCP before.5

SOURCES

1 Ferris FL, III. How effective are treatments for diabetic retinopathy? JAMA. 1993;269(10):1290-1291.

2 Verily Retinal Camera. Instructions for Use. Verily Life Sciences LLC.

3 Endocrine Society Endocrine Clinical Workforce: Supply and Demand Projections. Available from Endocrine Society. Accessed 11 August 2022.

4 Ferris FL, III. How effective are treatments for diabetic retinopathy? JAMA. 1993;269(10):1290-1291.

5 Verily survey of n=694 people with Type 1 (5+ years since diagnosis), Type 2, or Type 1.5 LADA diabetes. 2022. Verily Life Sciences LLC.